Integra Lifesciences Holdings (IART) Short term Debt (2010 - 2026)

Integra Lifesciences Holdings (IART) has 15 years of Short term Debt data on file, last reported at $38.8 million in Q1 2026.

• For the quarter ending Q1 2026, Short term Debt changed 0.0% year-over-year to $38.8 million; the trailing twelve-month figure through Mar 2026 stood at $38.8 million (changed 0.0% YoY), and the FY2025 full-year result was $38.8 million, down 93.24% from the prior year.
• Short term Debt was little changed at $38.8 million in Q1 2026, from $38.8 million in the prior quarter.
• In the past five years, Short term Debt ranged from a high of $573.2 million in Q4 2024 to a low of $4.8 million in Q2 2023.
• A 5-year average of $124.3 million and a median of $57.2 million in 2023 frame the typical range for Short term Debt.
• Across the five-year window, Short term Debt sank 95.69% in 2023 and jumped 3844.46% in 2024, its largest moves.
• Tracing IART's Short term Debt over 5 years: stood at $104.7 million in 2022, then plunged by 86.12% to $14.5 million in 2023, then jumped by 3844.46% to $573.2 million in 2024, then slumped by 93.24% to $38.8 million in 2025, then changed by 0.0% to $38.8 million in 2026.
• Business Quant data shows IART's Short term Debt at $38.8 million in Q1 2026, $38.8 million in Q4 2025, and $38.8 million in Q3 2025.